Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?

Author(s): Igor Govorov*, Stanislav Sitkin, Tatyana Pervunina, Alexey Moskvin, Denis Baranenko, Eduard Komlichenko.

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 22 , 2020

Become EABM
Become Reviewer


Omic-technologies (genomics, transcriptomics, proteomics and metabolomics) have become more important in current medical science. Among them, it is metabolomics that most accurately reflects the minor changes in body functioning, as it focuses on metabolome – the group of the metabolism products, both intermediate and end. Therefore, metabolomics is actively engaged in fundamental and clinical studies and search for potential biomarkers. The biomarker could be used in diagnostics, management and stratification of the patients, as well as in prognosing the outcomes. The good example is gynecology, since many gynecological diseases lack effective biomarkers. In the current review, we aimed to summarize the results of the studies, devoted to the search of potential metabolomic biomarkers for the most common gynecological diseases.

Keywords: Metabolomics, biomarkers, gynecology, uterine cervical neoplasms, ovarian neoplasms, endometriosis, polycystic ovary syndrome, leiomyoma.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [3611 - 3622]
Pages: 12
DOI: 10.2174/0929867326666190104124245
Price: $65

Article Metrics

PDF: 25